Previous close | 5.21 |
Open | 5.39 |
Bid | 5.86 x 900 |
Ask | 5.88 x 1100 |
Day's range | 5.39 - 6.71 |
52-week range | 5.11 - 44.95 |
Volume | |
Avg. volume | 434,470 |
Market cap | 200.467M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.41 |
Earnings date | 07 Mar 2022 - 11 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 44.40 |
CAMBRIDGE, Mass., May 16, 2022--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., April 21, 2022--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it is delivering a podium presentation at the 14th European Paediatric Neurology Society (EPNS) Congress, taking place in Glasgow, UK from April 28 - May 2, 2022.